Question 1: As the study is jointly funded, what impact does this have on the current cash runway to end FY24?
Question 2: Even with no impact (assuming fully funded or considered), there appears to be sufficient cash for 12 months, which really means there needs to be a a funding update either this or next quarter. Will it be CR or partnership. My bet would be partnership of sorts, fingers crossed it's not from a position of weakness.
Ann: Approval to start Efti & Bavencio trial in urothelial cancer, page-2
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.0¢ | 39.5¢ | $736.2K | 1.830M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 269404 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 136638 | 19 |
View Market Depth
| Last trade - 13.51pm 11/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |